Skip Navigation



Human Molecular Genetics Advance Access published online on March 12, 2008

Human Molecular Genetics, doi:10.1093/hmg/ddn083
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/13/1877    most recent
ddn083v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Grandis, M.
Right arrow Articles by Schenone, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grandis, M.
Right arrow Articles by Schenone, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Different Cellular and Molecular Mechanisms for Early and Late-onset Myelin Protein Zero Mutations

Marina Grandis

Department of Neurosciences, Ophthalmology and Genetics
University of Genova
16132 Genova, Italy

Tiziana Vigo

Institute of Molecular Bioimaging and Physiology (IBFM)-Section of Genova
Italian National Research Council
16132 Genova, Italy

Mario Passalacqua

Department of Experimental Medicine, Biochemistry Section
University of Genova
16132 Genova, Italy

Manisha Jain

Department of Neurology and Center for Molecular Medicine and Genetics
Wayne State University
48201 Detroit, MI, USA

Sara Scazzola

Institute of Molecular Bioimaging and Physiology (IBFM)-Section of Genova
Italian National Research Council
16132 Genova, Italy

Veronica La Padula

Department of Neurosciences, Ophthalmolgy and Genetics
University of Genova
16132 Genova, Italy

Michelle Brucal

Department of Neurology and Center for Molecular Medicine and Genetics
Wayne State University
48201 Detroit, MI, USA

Federica Benvenuto

Department of Neurosciences, Ophthalmology and Genetics
University of Genova
16132 Genova, Italy

Lucilla Nobbio

Department of Neurosciences, Ophthalmology and Genetics
University of Genova
16132 Genova, Italy

Angela Cadoni

Department of Experimental Medicine
University of Genova
16132 Genova, Italy

Gian Luigi Mancardi

Department of Neurosciences, Ophthalmolgy and Genetics
University of Genova
16132 Genova, Italy

John Kamholz

Department of Neurology and Center for Molecular Medicine and Genetics
Wayne State University
48201 Detroit, MI, USA

Michael E. Shy

Department of Neurology and Center for Molecular Medicine and Genetics
Wayne State University
48201 Detroit, MI, USA

Angelo Schenone

Department of Neurosciences, Ophthalmolgy and Genetics
University of Genova
16132 Genova, Italy
Institute of Molecular Bioimaging and Physiology (IBFM)-Section of Genova
Italian National Research Council
16132 Genova
Italy

Corresponding Author Marina Grandis Department of Neurosciences, Ophthalmolgy and Genetics University of Genova 16132 Genova, Italy Tel: 0039-010-3537057 Fax: 0039-010-3538639 e-mail: mgrandis{at}neurologia.unige.it

Received February 19, 2008; Revised February 19, 2008; Accepted March 10, 2008

Mutations in the gene MPZ, encoding myelin protein zero (MPZ), cause inherited neuropathies collectively called Charcot-Marie-Tooth type 1B (CMT1B). Based on the age of onset, clinical and pathological features, most MPZ mutations are separable into two groups: one causing a severe, early-onset, demyelinating neuropathy and a second, causing a late-onset neuropathy with prominent axonal loss.

To investigate potential pathomechanisms underlying the two phenotypes, we transiently transfected HeLa cells with two late-onset (T95M, H10P) and two early- onset (H52R, S22_W28 deletion) mutations and analyzed their effects on intracellular protein trafficking, glycosylation, cell viability and intercellular adhesion. We found that the two late-onset mutations were both transported to the cell membrane and moderately reduced MPZ-mediated intercellular adhesion. The two early-onset mutations caused two distinct abnormalities. H52R was correctly glycosylated and trafficked to the plasma membrane, but strongly affected intercellular adhesion. When co-expressed with wild-type MPZ (wtMPZ), a functional dominant negative effect was observed. Alternatively, S22_W28 deletion was retained within the cytoplasm and reduced both adhesion caused by wild type MPZ and cellular viability. Since the same trafficking patterns were observed in transfected murine Schwann cells, they are not an artifact of heterologous cell expression. Our results suggest that at least some late-onset mutations cause a partial loss of function in the transfected cells whereas multiple abnormal gain of function pathways can result in early-onset neuropathy. Further characterization of these pathways will lead to a better understanding of the pathogenesis of CMT1B and a rational basis for treating these debilitating inherited neuropathies.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Neurol. Neurosurg. PsychiatryHome page
M M Reilly and M E Shy
Diagnosis and new treatments in genetic neuropathies
J. Neurol. Neurosurg. Psychiatry, December 1, 2009; 80(12): 1304 - 1314.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
I. Katona, X. Wu, S. M. E. Feely, S. Sottile, C. E. Siskind, L. J. Miller, M. E. Shy, and J. Li
PMP22 expression in dermal nerve myelin from patients with CMT1A
Brain, July 1, 2009; 132(7): 1734 - 1740.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.